Enochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"
Enochian Biosciences emerged from the ashes of Dandrit and is currently valued at $238 million because of a preclinical, potential cure for HIV and a researcher that management has frequently named a "genius". But scientists doubt the company.
BY PETER THOMSEN AND KEVIN GRØNNEMANN
In 2017, Pandora billionaire René Sindlev took matters into his own hands. He had been a key shareholder of the cancer biotech Dandrit for years, but apparently he had had enough: He took the reins and put Dandrit to rest. The company had been working on a failed cancer vaccine, MCV, which according to Sindlev "couldn't even be given away".
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
